Guidelines of the Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms

Introduction. Strains of microorganisms resistant to antimicrobial agents are commonly found in medical units throughout most regions of the world, including Russia. This leads to lower antimicrobial therapy efficacy when treating nosocomial infections. In this regard, the timely implementation of adequate antibiotic therapy is of great importance.

The objective of the guidelines: To provide summarized information on contemporary approaches to microbiological diagnostics and the assessment of results, as well as the principles of rational use of antimicrobial and antifungal agents, including treatment of infections caused by multiple drug-resistant strains of microorganisms.

Subjects and methods. These guidelines are based on published data obtained in the course of randomized trials, as well as information presented in the provisions of international guidelines supported by high-level evidence. The guidelines were prepared by a working group of Russian experts with extensive experience in research and practical work in this area. On October 11, 2019, the final version of the guidelines was reviewed and approved at a joint meeting of the working group and representatives of the public organizations which initiated the development of these guidelines (Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), NGO Russian Sepsis Forum).

Conclusion. The guidelines reflect an interdisciplinary consensus of approaches to the diagnostics and antibiotic therapy of infections caused by multiresistant microorganisms. The provisions set forth should be used to decide on the strategy of empirical and etiotropic therapy of the most severe infections.

1. Аbdominalnaya khirurgicheskaya infektsiya. Rossiyskie natsionalnye rekomendatsii. [Abdominal surgical infection, Russian national guidelines]. B.R. Gelfand, А.I. Kirienko, N.N. Khachatryan. Moscow, 2018, 168 p.

2. Gusarov V.G., Lashenkova N.N., Petrova N.V. et al. Empirical antimicrobial treatment protocols as a tool to improve the quality of emergency medical care for patients with infection in a multidisciplinary surgical in-patient unit. Meditsinsky Alfavit. 2016, vol. 33, no. 4, Neotlozhnaya Meditsina, pp. 2-24. (In Russ.)

3. Gusarov V.G., Nesterova E.E., Oprischenko I.V. et al. Clinical and pharmacoeconomic results of empirical antimicrobial therapy protocol in a multidisciplinary hospital. Vestn. Natsionalnogo Mediko-Khirurgicheskogo Tsentra im. N.I. Pirogova, 2015, vol. 10, no. 4, pp. 100-103. (In Russ.)

4. Diagnostika i lechenoye mikozov v otdeleniyakh reanimatsii i intensivenoy terapii. Rossiyskiye rekomendatsii. [Diagnostics and treatment of fungal infection in critical care departments. Russian national guidelines]. N.N. Klimko, eds., 2nd ed., suppl. and amend., Moscow, Farmtek Publ., 2015, 96 p.

5. Karpov O.E., Zamyatin M.N., Gusarov V.G. et al. empirical antimicrobial therapy protocol in the in-patient unit of National Medical and Surgical Center named after N.I. Pirogov of the Russian Ministry of Health (4rd edition, 2018). Meditsinsky Alfavit. 2019, vol. 1, no. 16, Neotlozhnaya Meditsina i Kardiologiya, pp. 58-71. (In Russ.)

6. Kozlov S.N. Sovremennaya antimikrobnaya khimioterapiya. [Modern anti-microbe chemotherapy]. Kozlov S.N., Kozlov R.S. Moscow, Meditsinskoye Informatsionnoye Agentstvo Publ., 2017, 398 p.

7. Najgovzina N.V., Popova А.Yu., Biryukova E.E.et al. Optimization of activities aimed to control and prevent infections associated with medical care provision in the Russian Federation. ORGZDRAV, Novosti, Mneniya, Obuchenie, Vestnik VShOUZ, 2018, no. 1 (11), pp. 17-26. (In Russ.)

8. Nozokomialnaya pnevmoniya u vzroslykh. Rossiyskie natsionalnye rekomendatsii. [Nosocomial pneumonia in adults. Russian national guidelines]. Moscow, 2016, 176 p.

9. Plan meropriyatiy na 2019‒2024 gody po realizatsii Strategii preduprezhdeniya rasprostraneniya antimikrobnoy rezistentnosti v Rossiyskoy Federatsii na period do 2030 goda. [Action plan for 2019-2024 on the implementation of Strategy on Antimicrobial Resistance Prevention in the Russian Federation till 2030]. Approved by Edict no. 604-p by the RF Government as of March 30, 2019. Available: https://www.garant.ru/products/ipo/prime/doc/71677266/.

10. Popov V.A. Comparative characteristics of modern methods for carbapenemase products. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21, no. 2, pp. 125-133. (In Russ.)

11. Programma SKАT (Strategiya Kontrolya Аntimikrobnoy Terapii) pri okazanii statsionarnoy meditsinskoy pomoschi. Rossiyskie klinicheskie rekomendatsii. [SATC Program (Strategy for Anrimicrobial Therapy Control) for in-patient care medical care. Russian guidelines]. Beloborodova V.B., Brusina E.B., Kozlov R.S. et al. The Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, The Russian Association of Surgical Infection Specialists (RASKhI); National Professional Association for Control of Infections Associated with Medical Care; The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy; Russian Non-Governmental Organization Federation of Anesthesiologists and Resuscitators, Moscow, 2018.

12. Programma SKАT (Strategiya Kontrolya Аntimikrobnoy Terapii) pri okazanii statsionarnoy meditsinskoy pomoschi: Rossiyskie klinicheskie rekomendatsii. [SATC Program (Strategy for Anrimicrobial Therapy Control) for in-patient care medical care: Russian clinical guidelines]. S.V. Yakovlev, N.I. Briko, S.V. Sidorenko, D.N. Protsenko, eds., Moscow, Pero Publ., 2018, 156 p.

13. Romanov А.V., Dekhnich А.V., Sukhorukova M.V. et al. Antibiotic resistance in nosocomial strains of Staphylococcus aureus in hospitals of Russia: results of multi-center epidemiological study of MARATHON in 2015-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21. (in print) (In Russ.)

14. Rudnov V.А., Kulabukhov V.V. Sepsis-3: updated main definitions, potential problems and next practical steps. Messenger of Anesthesiology and Resuscitation, 2016, vol. 13, no. 4, pp. 4-11. (In Russ.)

15. Eydelshteyn M.V., Shek E.А., Sukhorukova M.V. et al. Antibiotic resistance in nosocomial strains of Enterobacterales in hospitals of Russia: results of multi-center epidemiological study of MARATHON in 2015-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21, no. 2, pp. 143-155. (In Russ.).

16. Shek E.А., Sukhorukova M.V., Eydelshteyn M.V. et al. Antibiotic resistance, carbapenemase products and genotypes of nosocomial strains of Аcinetobacter spp. in hospitals of Russia: results of multi-center epidemiological study of MARATHON in 2015-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21, no. 2, pp. 178-187. (In Russ.)

17. Shteynberg L.L., Upnitskiy А.А., Belousov Yu.B. Specific use of carbapenems for the treatment of nosocomial pneumonia. Lechebnoye Delo, 2014, no. 1, pp. 27-32. (In Russ.)

18. Eydelshteyn M.V., Shek E.А., Sukhorukova M.V. et al. Antibiotic resistance, carbapenemase products and genotypes of nosocomial strains of Pseudomonas aeruginosa in hospitals of Russia: results of multi-center epidemiological study of MARATHON in 2015-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21, no. 2, pp. 168-178. (In Russ.)

19. Yakovlev S.V., Suvorova M.P., Beloborodov V.B. et al. Prevalence and clinical value of nosocomial infection in the medical units of Russia: ERGINI study. Antibiotiki i Khimioterapiya, 2016, vol. 61, pp. 5-6. (In Russ.)

20. Aaftab G.P., Patil A.B., Medegar S. Multivariate analysis of risk factors for ESBL and AmpC producing Escherichia coli and Klebsiella pneumoniae at a Tertiary Care Hospital in Karnataka: A case control study. Indian Journal of Microbiology Research, 2018, vol. 5, no. 1, pp. 1-6.

21. Aloush V., Navon-Venezia S., Seigman-Igra Y. et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrobial Agents and Chemotherapy, 2006, vol. 50, no. 1, pp. 43-48.

22. Arruda E.A.G., Marinho I.S., Boulos M. et al. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infection Control and Hospital Epidemiology, 1999, vol. 20, no. 9, pp. 620-623.

23. Bassetti M., Righi E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Current Opinion in Critical Care, 2015, vol. 21, no. 5, pp. 402-411.

24. Bassetti M., Righi E., Carnelutti A. Bloodstream infections in the intensive care unit. Virulence, 2016, vol. 7, no. 3, pp. 267-279.

25. Biedenbach D.J. Toleman M., Walsh T.R. et al. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997–2004). Diagnostic Microbiology and Infectious Disease, 2006, vol. 54, no. 1, pp. 13‒21.

26. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy, 1995, vol. 39, no. 6, pp. 1211‒1233.

27. Callejo-Torre F., Bouza J.M.E., Astigarraga P.O. et al. Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission. Europe, 2016, vol. 5, pp. 1‒9.

28. Cao B., Wang H., Sun H. et al. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. Journal of Hospital Infection, 2004, vol. 57, no. 2, pp. 112‒118.

29. De Pascale G., Montini L., Pennisi M.A., et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care, 2014, vol. 18, no. 3, pp. R90. doi:10.1186/cc13858.

30. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical Infection Diseases, 2007, vol. 44, no. 2, pp. 159‒177.

31. Doumith M., Ellington M.J., Livermore D.M. et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. Journal of Antimicrobial Chemotherapy, 2009, vol. 63, no. 4, pp. 659‒667.

32. Doyle D., Peirano G., Lascols C. et al. Laboratory detection of Enterobacteriaceae that produce carbapenemases. Journal of Clinical Microbiology, 2012, vol. 50, no. 12, pp. 3877‒3880.

33. European Centres for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net).

34. Falcone M., Russo A., Venditti, M. et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clinical Infection Diseases, 2013, vol. 57, no. 11, pp. 1568‒1576.

35. Garnacho-Montero J., Dimopoulos G., Poulakou G. et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Medicine, 2015, vol. 41, no. 12, pp. 2057‒2075.

36. Gazin M., Lammens C., Goossens H. et al. Evaluation of GeneOhm VanR and Xpert vanA/vanB molecular assays for the rapid detection of vancomycin-resistant enterococci. European Journal of Clinical Microbiology & Infectious Diseases, 2012, vol. 31, no. 3, pp. 273‒276.

37. Ghibu L., Miftode E., Teodor A. et al. Risk factors for Pseudomonas aeruginosa infections, resistant to carbapenem. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti Din Lasi, 2010, vol. 114, no. 4, pp. 1012‒1016.

38. Giske C.G., Gezelius L., Samuelsen Ø. et al. A sensitive and specific phenotypic assay for detection of metallo‐β‐lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clinical Microbiology and Infection, 2011, vol. 17, no. 4, pp. 552‒556.

39. Gniadkowski M. Evolution of extended‐spectrum β‐lactamases by mutation. Clinical Microbiology and Infection, 2008, vol. 14, pp. 11‒32.

40. Goyal D., Dean N., Neill S. et al. Risk Factors for Community-Acquired Extended-Spectrum Beta-Lactamase – Producing Enterobacteriaceae Infections ‒ A Retrospective Study of Symptomatic Urinary Tract Infections. Open forum infectious diseases. US, Oxford University Press, 2019, vol. 6, no. 2, ofy357., https://doi.org/10.1093/ofid/ofy357.

41. Grabein B., Graninger W., Baño J.R. et al. Intravenous Fosfomycin ‒ back to the future. Systematic review and meta-analysis of the clinical literature. Clinical Microbiology and Infection, 2017, vol. 23, no. 6, pp. 363‒372.

42. Greissl C., Saleh A., Hamprecht A. Rapid detection of OXA-48-like, KPC, NDM, and VIM carbapenemases in Enterobacterales by a new multiplex immunochromatographic test. European Journal of Clinical Microbiology & Infectious Diseases, 2019, vol. 38, no. 2, pp. 331‒335.

43. Haley C.C., Mittal D., LaViolette et al. Methicillin-resistant Staphylococcus aureus infection or colonization present at hospital admission: multivariable risk factor screening to increase efficiency of surveillance culturing. Journal of Clinical Microbiology, 2007, vol. 45, no. 9, pp. 3031‒3038.

44. Kao K.C., Chen C.B., Hu H.C. et al. Risk factors of methicillin-resistant Staphylococcus aureus infection and correlation with nasal colonization based on molecular genotyping in medical intensive care units: a prospective observational study. Medicine, 2015, vol. 94, no. 28. doi: 10.1097/MD.0000000000001100,

45. Liu C., Bayer A., Cosgrove S.E. et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infection Diseases, 2011, vol. 52, no. 3, pp. e18‒e55.

46. Merchant S., Proudfoot E.M., Quadri H.N. et al. Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis. Journal of Global Antimicrobial Resistance, 2018, vol. 14, pp. 33‒44.

47. Nicolas-Chanoine M.H., Vigan M., Laouenan C. et al. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study. European Journal of Clinical Microbiology & Infectious Diseases, 2019, vol. 38, no. 2, pp. 383‒393.

48. Ohmagari N., Hanna H., Graviss L. et al. Risk factors for infections with multidrug‐resistant Pseudomonas aeruginosa in patients with cancer. Cancer, 2005, vol. 104, no. 1, pp. 205‒212.

49. Paramythiotou E., Lucet J.C., Timsit J.F. et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clinical Infection Diseases, 2004, vol. 38, no. 5, pp. 670‒677.

50. Predic M., Delano J.P., Tremblay E. et al. risk factors for carbapenem-resistant Enterobacteriaceae infection. American Journal of Infection Control, 2017, vol. 45, no. 6, pp. S14. DOI: https://doi.org/10.1016/j.ajic.2017.04.271.

51. Queenan A.M., Bush K. Carbapenemases: the versatile β-lactamases. Clinical Microbiology Reviews, 2007, vol. 20, no. 3, pp. 440‒458.

52. Red Book. 29 Edition; American Academy of Pediatrics. 2012.

53. Rhodes A., Evans L.E., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine, 2017, vol. 43, no. 3, pp. 304‒377.

54. Sfeir M.M., Hayden J.A., Fauntleroy K.A. et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing Enterobacteriaceae. Journal of Clinical Microbiology, 2019, vol. 57, no. 5. doi:10.1128/JCM.01757-18.

55. Søraas A., Sundsfjord A., Sandven I. et al. Risk factors for community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae – a case-control study in a low prevalence country. PloS one, 2013, vol. 8, no. 7, pp. e69581. doi:10.1371/journal.pone.0069581.

56. Taccone F.S., Laterre P.F., Spapen H. et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Critical Care, 2010, vol. 14, no. 2, pp. R53. https://doi.org/10.1093/cid/ciq146.

57. Tuon F.F., Kruger M., Terreri M. et al. Klebsiella ESBL bacteremia-mortality and risk factors. Brazilian Journal of Infectious Diseases, 2011, vol. 15, no. 6, pp. 594‒598.

58. Udy A.A., Baptista J.P., Lim, N.L. et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Critical Care Medicine, 2014, vol. 42, no. 3, pp. 520‒527.

59. Vading M. Samuelsen Ø., Haldorsen B. et al. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase‐producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clinical Microbiology and Infection, 2011, vol. 17, no. 5, pp. 668‒674.

60. Van der Zwaluw K., de Haan K., Pluister A. et al. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PloS one, 2015, vol. 10, no. 3, pp. e0123690.

61. Van Dijk K. et al. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin. Clinical Microbiology and Infection, 2014, vol. 20, no. 4, pp. 345‒349.

62. Wener K.M., Schechner V., Gold H.S. et al. Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β-lactamase-producing Klebsiella species in hospitalized patients. Antimicrobial Agents and Chemotherapy, 2010, vol. 54, no. 5. doi:10.1128/AAC.01131-09.

63. WHO: Antimicrobial resistance: global report on surveillance, 2014.

64. Willemsen I. Overdevest I., al Naiemi N. et al. New diagnostic microarray (Check-KPC ESBL) for detection and identification of extended-spectrum beta-lactamases in highly resistant Enterobacteriaceae. Journal of Clinical Microbiology, 2011, vol. 49, no. 8, pp. 2985-2987.

65. Yu Z. Pang X., Wu X. et al. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PloS one, 2018, vol. 13, no. 7, pp. e0201667.

66. Zaha D.C., Kiss R., Hegedűs C. et al. Recent Advances in Investigation, Prevention, and Management of Healthcare-Associated Infections (HAIs): Resistant Multidrug Strain Colonization and Its Risk Factors in an Intensive Care Unit of a University Hospital. BioMed Research International, 2019. doi: 10.1155/2019/2510875.eCollection2019.

67. Zamyatin M., Gusarov V., Petrova N. et al. Results of antimicrobial stewardship programme implementation in multidisciplinary hospital. ICU Management & Practice, 2018, vol. 18, no. 2, pp. 125‒127.